Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page shows a new revision tag: v3.6.3, replacing the previous v3.6.1. This indicates a newer version of the page content.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision: v3.6.1 is now displayed, replacing the previous v3.6.0. This reflects a frontend version update and does not modify study details or content on the page.SummaryDifference0.0%

- Check34 days agoChange DetectedThe study page now shows 'No longer looking for participants', signaling that recruitment is closed for this study. Additional navigational or labeling updates were applied, including new sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study', and a minor heading formatting change from 'Intervention / Treatment' to 'Intervention/Treatment'.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page footer now displays Revision: v3.5.5, replacing Revision: v3.5.4. This indicates a minor update to the page's revision history without changing its content.SummaryDifference0.0%

- Check56 days agoChange DetectedThe study locations list now includes Taebuk, Chungcheongbuk-do, South Korea (28644) and previously listed Jungbuk (28644) was removed; the page revision was updated from v3.5.3 to v3.5.4.SummaryDifference0.0%

- Check77 days agoChange DetectedThe revision tag has been updated to v3.5.3, replacing the previous v3.5.0 in the revision history. This represents a metadata update with no substantive changes to the study details.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.